Initiating statins in the elderly: The evolving challenge

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 15, Issue 2, 2008, Pages 182-187

  Walker, D Benson ^a   Jacobson, Terry A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cerebrovascular accident (CVA); Coronary heart disease (CHD); Elderly; Statins

Indexed keywords

AMIODARONE; ANTIFUNGAL AGENT; ATORVASTATIN; CYCLOSPORIN; CYTOCHROME P450 INHIBITOR; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; PLACEBO; PRAVASTATIN; PROTEIN INHIBITOR;

AGED; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIVER FUNCTION TEST; META ANALYSIS; MUSCULOSKELETAL DISEASE; MYOPATHY; NEUROLOGIC DISEASE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROTEINURIA; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; STROKE; SYSTEMATIC REVIEW; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; MIDDLE AGED; SAFETY;

AGED; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; DIABETIC ANGIOPATHIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; PRAVASTATIN; PRIMARY PREVENTION; SAFETY; STROKE;

EID: 42449097700     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3282f7cd6d     Document Type: Review

References (23)

1. American Heart Association. 2007 Statistical Fact Sheet. Older americans and cardiovascular diseases: statistics. http://www.americanheart.org/presenter. jhtml?identifier=2011. [Accessed 1 November 2007]. This website provides the most comprehensive, updated statistics for cardiovascular disease including delineation by population and risk factors.
2. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339:1349-1357.
3. Cournot M, Cambou JP, Quentzel S, Danchin N. Key factors associated with the under-prescription of statins in elderly coronary heart disease patients: Results from the ELIAGE and ELICOEUR surveys. Int J Cardiol 2006; 111:12-18.
4. Grundy SM, Cleeman JI, Merz CN, et al., for the National Heart, Lung, and Blood Institute; American College of Cardiology Foundation, and the American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-239.
5. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the cholesterol and recurrent events(CARE) trial. Ann Intern Med 1998; 129:681-689.
6. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high risk individuals: a randomized placebo-controlled trial. JAMA 2002; 287:3215-3222.
8. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005; 366:1267-1278. A large meta-analysis of 90 056 patients in 14 randomized trials investigated statin use. Meta-analysis included a large elderly cohort of 34 982 patients, and showed benefits of statins in patients both >65 and >75 years.
9. Shepherd J, Biauw GJ, Murphy MB, et al. Pravastatin in elderly individuals of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002; 360:1623-1630.
10. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004; 364:685-696.
11. Shepherd J, Cobbe M, Ford I, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1307.
12. Ford I, Murray H, Packard CJ, et al., for the West of Scotland Coronary Prevention Study Group (WOSCOPS). Long-TermFollow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007; 357:1477-1486. A randomized trial enrolled men between the ages of 45 and 64 years, with hypercholesterolemia, but without history of MI. The trial provided robust data at 5 then 10 years and finally over the course of the entire study. The WOSCOPS data provide a robust long-term evaluation of statin efficacy in the primary prevention of CHD death and is a hallmark for future studies focusing in on long-term primary prevention in an aging population
13. Heart Disease and Stroke Statistics: 2007 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115:e69-e171. This report provides updated statistics on stroke with breakdown by age and population.
14. Wenger NK, Lewis SJ, Herrington DH, et al., for the Treating to New Targets (TNT) Study Steering Committee and Investigators. Outcomes of using highor low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 2007; 147:1-9. This study was a randomized, double-blinded trial of over 3809 patients >65 years with CHD who received either low (10 mg) or high (80 mg) dose atorvastatin. The trial not only showed additional benefit from higher dose, but also trend towards CVA reduction.
15. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al., Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. Highdose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549-559. In a randomized trial, 4731 patients, mean age of 63 years, with known TIA or CVA, but no history of CHD, were given atorvastatin or placebo. SPARCL showed significant CVA risk reduction for patients on statin therapy.
16. Kuller LH, Shemanski L, Psaty BM, et al. Subclinical disease as an independent risk factor for cardiovascular disease. Circulation 1995; 92:720-726.
17. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007; 297:611-619. This study examined several risk factors in 24 558 healthy women, aged 45 years or older, to determine incidence of cardiovascular events. Investigators developed global cardiovascular risk assessment algorithms and found improved accuracy compared to Adult Treatment Panel III classifications. Furthermore, several factors, including high-sensitive C-reactive protein were also accurate predictors of cardiovascular events.
18. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arteriorscler Thromb Vasc Biol 1997; 17:1121-1127.
19. Cao JJ, Arnold AM, Manolio TA, et al. Association of carotid artery intimamedia thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation 2007; 116:32-38.
20. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355:2631-2639. This was an investigation of several novel biomarkers that could serve predictors of CHD events. The study found B-type natriuretic peptide (BNP), C-reactive protein, the urinary albumin-to-creatinine ratio, homocysteine, and renin were positive biomarkers for death and BNP and the urinary albumin-to-creatinine ratio were positive for major cardiovascular events.
21. McKenney JM, Davidson MH, Jacobson TA, Guyton JR, National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006; 97 (8A):89C-94C. This report provides comprehensive recommendations for monitoring patients on statins and addresses most severe and frequent adverse effects.
22. Ali R, Alexander KP. Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence. Am J Geriatr Pharmacother 2007; 5:52-63.
23. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther 2006; 28:26-35. This was a large meta-analysis of 18 trials including 71 108 persons and 301374 person-years follow up. Statins were associated with a 26% reduction in the risk of a clinical cardiovascular event (OR 0.74; 95% CI, 0.69-0.80; P<0.001) and a low number needed to treat. Overall, clinicians who treat 1000 patients would prevent 37 cardiovascular events with only five adverse effects of any nature. Serious adverse effects of creatinine kinase elevation or rhabdomyolysis were more rare with number needed to harm of 3400 and 7428 respectively.